1. Aksel' E.M. Statistika zlokachestvennykh novoobrazovaniĭ zheludochno‐kishechnogo trakta. Sibirskiĭ onkologicheskiĭ zhurnal. 2017; 16 (3): 5-11. [Axel’ E.M. Gastrointestinal cancer statistics. Siberian Journal of Oncology. 2017; 16 (3): 5-11. (in Russian)]. https://doi.org/10.21294/1814‐ 4861‐2017‐3‐5‐11.
2. Aliev F.Sh., Desyatov E.N., Krutskikh A.G., Aliev V.F., Leĭmanchenko P.I. Epidemiologiya kolorektal'nogo raka: mirovye i regio‐ nal'nye tendentsii. Meditsinskaya nauka i obrazovanie Urala. 2016; 17 (4): 125-128. [Aliev F.Sh., Desyatov E.N., Krutskih A.G., Aliev V.F., Leimanchenko P.I. The epidemiology of colorectal cancer: world and regional tendencies. Medical Science and Education of Ural. 2016; 17 (4): 125-128. (in Russian)].
3. Patyutko Yu.I., Sagaĭdak I.V., Polyakov A.N., Podluzhnyĭ D.V., Chernoglazova E.V., Chistyakova O.V., Kosyrev V.Yu. Khirurgicheskoe i kombinirovannoe lechenie bol'nykh kolorektal'nym rakom s meta‐ staticheskim porazheniem pecheni. Onkologicheskaya koloproktologiya. 2011; 1: 32-40. [Patyutko Y.I., Sagaidak I.V., Polyakov A.N., Podluzhny D.V.1, Chernoglazova E.V., Chistyakova O.V., Chuchuyev E.S., Gakhramanov A.D., Kosyrev V.Y. Surgery and chemotherapy plus surgery for patients with colorectal cancer liver metastases. Colorectal Oncology. 2011; 1: 32-40. (in Russian)].
4. Cady B., McDermott W.V. Major hepatic resection for metachronous metastases from colon cancer. Ann Surg. 1985 Feb; 201 (2): 204-9.
5. Sakaeva D.D. Ad"yuvantnoe i neoad"yuvantnoe lechenie bol'nykh rakom obodochnoĭ i pryamoĭ kishki. Prakticheskaya onkologiya. 2005; 6 (2): 103-111. [Sakaeva D.D. Adjuvant and neoadjuvant treatment of colorectal cancer patients. Practical Oncology. 2005; 6 (2): 103-111. (in Russian)].
6. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first‐ line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug; 18 (16): 2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938.
7. Afanas'ev S.G., Startseva Zh.A., Tarasova A.S., Usova A.V., Samtsov E.N. Rezul'taty kombinirovannogo lecheniya raka pryamoĭ kishki s primeneniem prolongirovannoĭ predoperatsionnoĭ khimio‐ luchevoĭ terapii. Sibirskiĭ onkologicheskiĭ zhurnal. 2012; 6: 5-12. [Afanasyev S.G., Startseva Zh.A., Tarasova A.S., Usova A.V., Samtsov E.N. Results of combined modality treatment including preoperative plolonged chemotherary for rectal cancer. Siberian Journal of Oncology. 2012. 6: 5-12. (in Russian)].
8. Mekenkamp L.J., Koopman M., Teerenstra S., van Krieken J.H., Mol L., Nagtegaal I.D., Punt C.J. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010 Jul 13; 103 (2): 159-64. https://doi.org/10.1038/ sj.bjc.6605737.
9. Efetov V.M., Efetov S.V., Cheripko O.N. Retsidivy raka pryamoĭ kishki. Onkologiya. 2006; 8 (2): 176-180. [Efetov V.M., Efetov S.V., Cheripko O.N. Rectal cancer relapses. Oncology. 2006; 8 (2): 176-180. (in Russian)].
10. Belyaeva A.V., Moiseenko A.B., Gulyaev A.V. Sovremennye pred‐ stavleniya o prognosticheskikh faktorakh kolorektal'nogo raka. Vopro‐ sy onkologii. 2011; 57 (3): 279-285. [Belyaev A.V., Moiseenko A.B., Gulyaev A.V. Current views on prognostic factors for colorectal cancer. Problems in Oncology. 2011; 57 (3): 279-285. (in Russian)].
11. Cheripko O.N. Faktory, vliyayushchie na chastotu vozniknoveniya retsidivov raka pryamoĭ kishki. Onkologiya. 2002; 4 (3): 206-208. [Cheripko O.N. Factors effecting the freguency of relapces of rectal cancer. Oncology. 2002; 4 (3): 206-208. (in Russian)].
12. Ding P.R., An X., Zhang R.X., Fang Y.J., Li L.R., Chen G., Wu X.J., Lu Z.H., Lin J.Z., Kong L.H., Wan D.S., Pan Z.Z. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following cura‐ tive resection for stage IIA colon cancer. Int J Colorectal Dis. 2010 Dec; 25 (12): 1427-33. https://doi.org/10.1007/s00384‐010‐1052‐0.
13. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., Hoon D.S. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005 Apr 20; 23 (12): 2744-53. https://doi.org/10.1200/JCO.2005.07.078.
14. Hutchins G., Southward K., Handley K., Magill L., Beaumont C., Stahlschmidt J., Richman S., Chambers P., Seymour M., Kerr D., Gray R., Quirke P. Value of mismatch repair, KRAS, and BRAF mutations in predict‐ ing recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011 Apr 1; 29 (10): 1261-70. https://doi.org/10.1200/JCO.2010.30.1366.
15. Mazurenko N.N., Gagarin I.M., Tsyganova I.V., Mochal'nikova V.V., Breder V.V., Gorbunova V.A. Chastota i spektr mutatsiĭ KRAS v meta‐ staticheskom kolorektal'nom rake. Voprosy onkologii. 2013; 59 (6): 751-755. [Mazurenko N.N., Gagarin I.M., Tsyganova I.V., Mochalnikova V.V., Breder V.V., Gorbunova V.A. The frequency and spectrum of KRAS mutations in metastatic colorectal cancer. Problems in Oncology. 2013; 59 (6): 751-755. (in Russian)].
16. Imyanitov E.N. Kliniko‐molekulyarnye aspekty kolorektal'‐ nogo raka: etiopatogenez, profilaktika, individualizatsiya lecheniya. Prakticheskaya onkologiya. 2005; 6 (2): 65-70. [Imyanitov E.N. Clinical and molecular aspects of colorectal cancer: etiopathogenesis, prevention, treatment individualization. Practical Oncology. 2005; 6 (2): 65-70. (in Russian)].
17. Müller O. Identification of colon cancer patients by molecular diagnosis. Dig Dis. 2003; 21 (4): 315-319. https://doi.org/10.1159/000075354.